No problem, unfortunately I didn't avoid it, so I took a reasonable hit on that one.
Nature of the industry I guess, high-risk, high-reward.
Rereading the latest presentation, it seems they have sufficient clinical data at present to get CE Mark. The Pivotal study with 1st patient recruited end of Q3 is for IDE approval in Q4. PMA approval is still a while away (2nd half 2017) but if they are earning revenues in Europe, Australia and Canada in the meantime, should be ok
I hope rgc can offer his opinion (as well as Bioshares) because currently I am non-holder but am very keen to buy in.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.11 |
Change
0.025(2.30%) |
Mkt cap ! $20.89M | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.11 | $1.09 | $26.73K | 24.35K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6807 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.12 | 6617 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| OSL (ASX) Chart |